Compare BFLY & KARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BFLY | KARD |
|---|---|---|
| Founded | 2011 | 2023 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Electronics | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 1.2B |
| IPO Year | 2020 | 2026 |
| Metric | BFLY | KARD |
|---|---|---|
| Price | $6.64 | $12.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 6 |
| Target Price | $11.17 | ★ $38.67 |
| AVG Volume (30 Days) | ★ 4.6M | 600.4K |
| Earning Date | 10-29-2026 | 11-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 8.82 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $97,610,000.00 | N/A |
| Revenue This Year | $24.76 | N/A |
| Revenue Next Year | $23.86 | $50.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 18.96 | N/A |
| 52 Week Low | $1.90 | $12.23 |
| 52 Week High | $10.21 | $27.00 |
| Indicator | BFLY | KARD |
|---|---|---|
| Relative Strength Index (RSI) | 35.36 | 35.50 |
| Support Level | $6.35 | $12.23 |
| Resistance Level | $9.86 | $15.93 |
| Average True Range (ATR) | 0.54 | 1.32 |
| MACD | -0.19 | 0.08 |
| Stochastic Oscillator | 1.52 | 13.24 |
Butterfly Network Inc is a digital health business transforming care with handheld, whole-body ultrasound. Powered by its proprietary Ultrasound-on-Chip technology, its solution enables the acquisition of imaging information from an affordable, powerful device that fits in a healthcare professional's pocket with a combination of cloud-connected software and hardware technology that is easily accessed through a mobile application. Butterfly iQ+ is an ultrasound device that can perform whole-body imaging in a single handheld probe using semiconductor technology. The company operates in one reportable segment, which includes all activities related to the development, manufacture, and sale of the Company's products, software, and other services.
Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.